ArticleFrontiers in neurology2021
Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.Neurodegenerative disease management · 2024Trial
- A proof-of-concept study on the effectiveness of botulinum toxin on spasticity plus syndrome in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- The Spanish REAL project: expert allergist guidance on allergen immunotherapy based on mixtures from different allergenic sources.Frontiers in allergy · 2026Article
- Review
- Article
- Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain.Frontiers in neurology · 2024Article
- Effect of nabiximols oromucosal spray (SativexDrugs in context · 2024Article
- Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.Frontiers in immunology · 2024Review
- Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis.Frontiers in neurology · 2024Article
- ATherapeutic advances in neurological disorders · 2023Article
- A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.European journal of neurology · 2022Article
- Activating cannabinoid receptor 2 preserves axonal health through GSK-3β/NRF2 axis in adrenoleukodystrophy.Acta neuropathologica · 2022Article
- Clinical insights on the spasticity-plus syndrome in multiple sclerosis.Frontiers in neurology · 2022Article
- Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.